Dr. Patton has served on the Aerami Therapeutics Board since 2009, and is the founder, former Chief Executive Officer and former Chairman of the Board of Aerami. He is Executive Chairman of iPharma Limited, an inhalation contract development research organization and beginning in February 2020 became Chief Executive Officer of Tesio Pharmaceuticals, an injectable osteoarthritis company. From 1990 to 2008, Dr. Patton served in a variety of roles at Inhale/Nektar Therapeutics, which he co-founded, focusing on inhalation and PEGylation technologies, including as Vice President of Research from 1991 to 2001, Chief Scientific Officer from November 2001 to March 2008, and a member of the board of directors from 1990 to 2008. Dr. Patton cofounded and served as a member of the board of directors of InCarda Therapeutics, Inc., an inhalation focused cardiovascular company from 2009 until 2015. In 1998, Dr. Patton was the founding investor of Halozyme Therapeutics, Inc., a biopharmaceutical company, and served as a member of its board of directors from 2004 until 2015. From 1985 to 1990, Dr. Patton served as the head of the drug delivery group of Genentech, Inc., a biotechnology company. From 1979 to 1985, Dr. Patton served as a professor of microbiology and of marine sciences at the University of Georgia. Dr. Patton previously served as a member of the board of directors of Activaero GmbH, a drug delivery company, from 2007 until its acquisition by Vectura Group plc in March 2014. Dr. Patton also serves on the advisory board of the Eberly College of Science at Pennsylvania State University and is a member of the Scripps Institution of Oceanography Advisory Counsel. Dr. Patton earned a B.S. in Zoology from Pennsylvania State University, an M.S. in Oceanography from the University of Rhode Island, and a Ph.D. in Biology from the University of California, San Diego. Dr. Patton also has held post doctorate positions in Biomedicine at Harvard Medical School and the University of Lund in Sweden.